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ma, and infectious mononucleosis. However,  WZhet DNA 
was detected in vitro in EBV-infected AGS gastric cancer 
cells. Additionally, transient transfection of infected AGS 
gastric cancer cells showed that viral replication could be 
induced by a  WZhet  plasmid.  Conclusion: This is the first ev-
idence that  WZhet induces the EBV lytic cycle in an epithelial 
cell line. Our negative findings in natural settings suggest 
that  WZhet is a defective viral product that thrives in the ab-
sence of a host immune system but is rarely present in vivo. 
 Copyright © 2009 S. Karger AG, Basel 
 Introduction 
 Several forms of cancer have been linked to Epstein-
Barr virus (EBV) by virtue of the presence of viral DNA 
or gene products in tumor cells  [1–6] . The gold-standard 
assay for defining EBV in a tumor is EBV-encoded RNA 
 ( EBER ) in situ hybridization in paraffin-embedded tissue 
sections, because  EBER stains are sensitive and specific 
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 Abstract 
 Objective:  WZhet  is a rearranged and partially deleted form 
of the Epstein-Barr virus (EBV) genome in which the  BamH1W 
region becomes juxtaposed with and activates  BZLF1 , result-
ing in constitutive viral replication. We tested whether  WZhet 
induces viral replication in epithelial cells, and we studied its 
prevalence in a wide range of lesional tissues arising in vivo. 
 Methods: A quantitative real-time PCR assay targeting EBV 
 WZhet DNA was developed to measure this recombinant 
form of the EBV genome.  Results:  WZhet  DNA was undetect-
able in any of 324 plasma or paraffin-embedded tissue sam-
ples from patients with EBV-associated and EBV-negative 
disorders. These included specimens from patients with 
Hodgkin or non-Hodgkin lymphoma, post-transplant lym-
phoproliferation, nasopharyngeal or gastric adenocarcino-
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for latent EBV infection, and the virus can be localized to 
specific cell types by microscopic interpretation. How-
ever, the sensitivity of  EBER histochemical stains has 
been called into question by investigators who showed, by 
molecular and immunohistochemical assays, that EBV 
was present in some  EBER -negative tumors  [3, 5, 7–10] . 
These data are controversial because some laboratory as-
says for EBV are not designed to sensitively and specifi-
cally detect tumor-associated EBV or to distinguish it 
from the latent EBV normally carried by most humans in 
a subpopulation of benign B lymphocytes. In addition, 
the ‘hit-and-run’ hypothesis has been proposed to ex-
plain some of these discrepancies. This hypothesis states 
that segments of EBV DNA or EBV gene products are un-
detected in certain cells or entire tumors because por-
tions of the EBV genome have been lost, rearranged, and/
or integrated into host chromosomal DNA  [3, 6] . For ex-
ample, if the  EBER gene were deleted during tumorigen-
esis, then the resulting tumor might be falsely diagnosed 
as EBV-negative if  EBER hybridization were the only as-
say used to test for presence of the virus.
 One well-known rearranged and partially deleted 
form of the EBV genome is called  WZhet . This defective 
EBV genome forms self-contained replicons that multi-
ply independently of the standard EBV genome and are 
capable of cell-to-cell spread  [11] . In this abnormally rear-
ranged form of EBV, large segments of viral DNA have 
been deleted and the remaining four portions, two from 
the terminal ends and two from the center of the genome, 
are rearranged, resulting in the juxtaposition of the oth-
erwise distant  BamH1W and  BamH1Z leftward reading 
frame 1  ( BZLF1 ) regions, thus the name  WZhet  [6] . This 
rearrangement results in constitutive expression of the 
immediate early gene protein, BZLF1, which triggers ac-
tive viral replication of any intact wild-type EBV DNA 
that resides in the same cell  [12] . Other retained sequenc-
es include the origin of viral replication, those sequences 
that are required for packaging viral DNA into virions, 
and open reading frames for  BZLF1 ,  BMLF1 , and  BILF1 
which encode proteins that transactivate lytic gene ex-
pression  [6] . It is postulated that  WZhet is not just an ar-
tifact but rather a novel mechanism by which the virus 
can switch, via recombinatorial events, from latent to lyt-
ic phases of its life cycle  [13] .
 WZhet DNA was first identified in the Burkitt lym-
phoma cell line, P3HR-1  [14–17] , and it has since been 
detected in oral hairy leukoplakia, thymic cancer, Burkitt 
lymphoma, Hodgkin lymphoma, and idiopathic pulmo-
nary fibrosis  [3, 6, 13, 18–20] .  WZhet DNA is thought to 
be unstable in cells lacking wild-type EBV genome  [13] , 
but  WZhet has also been detected in  EBER -negative tu-
mors suggesting that it could exist in cells lacking the 
gold-standard marker of latent EBV infection  [3, 6, 13, 16, 
18, 19] .
 In this study, a novel quantitative real-time PCR assay 
targeting EBV  WZhet DNA was developed in order to 
measure levels of  WZhet in human tissues including be-
nign and malignant biopsy tissue and plasma from pa-
tients with various diseases, some of which are EBV-re-
lated. To show that  WZhet could induce lytic viral repli-
cation,  WZhet plasmid was transfected into an infected 
gastric epithelial cell line and levels of viral DNA were 
subsequently measured using Q-PCR.
 Methods 
 Biopsy Tissue Samples 
 Paraffin-embedded tissue blocks (n = 287) were retrieved 
from the archives of our clinical and research laboratories under 
a protocol approved by our Institutional Review Board. Cases 
were selected to represent various normal and disease conditions, 
some of which were known to be EBV-related diseases.  EBER -
positive tissues included AIDS lymphoma (n = 5), AIDS-related 
Hodgkin lymphoma (n = 3), Hodgkin lymphoma (n = 5), non-
Hodgkin lymphoma (n = 2), nasopharyngeal carcinoma (n = 2), 
and post-transplant lymphoproliferative disorder (PTLD; n = 3). 
 EBER -negative tissues included AIDS lymphoma (n = 7), AIDS-
related Hodgkin lymphoma (n = 1), and Hodgkin lymphoma
(n = 4).
 Other paraffin-embedded tissues included 113 gastric adeno-
carcinomas (11  EBER -positive and 102  EBER -negative); 89 gastri-
tis samples from adults (n = 6) or from adults who also had gastric 
adenocarcinoma elsewhere in the stomach (n = 33) or from chil-
dren ranging in age from 2 months to 20 years (n = 50); normal 
gastric mucosa from patients undergoing gastric bypass surgery 
(n = 5); normal colon (n = 9); meningioma (n = 11); Crohn’s disease 
(n = 9), and ulcerative colitis (n = 11). Histological sectioning and 
DNA extraction was performed using a manual xylene-based 
protocol as previously described  [21] . DNA from paraffin-embed-
ded oral hairy leukoplakia tissue (n = 8) was provided by Dr. Jen-
nifer Webster-Cyriaque at University of North Carolina at Chapel 
Hill. 
 Total EBV viral load was measured by Q-PCR using a TaqMan 
probe targeting the  BamH1W viral sequence as previously de-
scribed  [21] . A Q-PCR for the human  APOB gene served to insure 
that at least 50 cells were represented in each reaction. In addition, 
 APOB levels served as a normalizer by which to compare viral 
concentrations across tissues of diverse size by reporting viral 
loads as a ratio of copies of EBV DNA per 100,000 cells as previ-
ously described  [21, 22] .
 EBV-Encoded RNA in situ Hybridization 
 In every tumor tissue,  EBER  in situ hybridization was per-
formed using either a manual method with fluorescein-labeled 
oligonulceotide  EBER probe and the Super-Sensitive Poly-HRP 
ISH Non-Biotin Detection Kit (Biogenex, San Ramon, Calif., 
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USA) with methyl green counterstain, or by an automated meth-
od using fluorescein-labeled  EBER probe on the Ventana Bench-
mark in situ hybridization system. Oligo(d)T probe served as an 
RNA preservation control in both assays. A tumor was considered 
 EBER -negative if  EBER staining was undetected or was expressed 
only in benign-appearing lymphoid cells, and  EBER -positive if 
the signal was localized to neoplastic cells.
 Plasma and Blood Samples 
 Frozen and fresh human plasma samples (n = 37) having high 
EBV viral loads were obtained from the archives of our clinical 
and research laboratories. EBV viral load had been measured by 
Q-PCR using a TaqMan probe targeting the  BamH1W viral se-
quence as previously described  [21] . These samples came from 
patients with histologically proven AIDS-related lymphoma (n = 
10), post-transplant lymphoproliferative disorder (n = 6), or infec-
tious mononucleosis (n = 12), and healthy blood donors (n = 9). 
Infectious mononucleosis was diagnosed by heterophile anti-
body-positivity among clinically ill patients seen by the Univer-
sity Student Health Service.
 DNA was extracted as previously described  [21] . Briefly, total 
DNA was purified from 200   l of plasma using the QIAmp Blood 
Kit (Qiagen, Inc., Valencia, Calif., USA) following the manufac-
turer’s protocol with elution into 50   l of AE buffer (Qiagen). 
Prior to extraction, the plasma was spiked with 2   l of IPC (Taq-
Man Exogenous Internal Positive Control DNA, Applied Biosys-
tems (ABI), Foster City, Calif., USA) and this was subsequently 
amplified to control for the efficacy of extraction and amplifica-
tion.
 WZhet Quantitative Real-Time Polymerase Chain Reaction 
Assay 
 The DNA sequence for EBV ‘BamHI segment heterogeneous 
(het) 2.7 DNA’ ( WZhet ; NCBI Accession No. M20820) served as 
the basis for designing PCR primers and a TaqMan probe span-
ning nucleotide numbers 1507–1655 using Primer Express 2.0 
software (ABI): The forward primer targets  BZLF1 : 5  -GAC ATT 
CAT CAT TTA GAA ATG TAT CCA-3  ; The reverse primer tar-
gets  BamH1W : 5  -TTC TCA GTC CAG CGC GTT TA-3  ; TaqMan 
probe targets  BamH1W : 5  (6FAM)TGG TCC CCC TCC CTA 
GAA CTG AC(TAMRA)-3  . The Q-PCR assay targets a 149-bp 
region of the  WZhet DNA sequence as depicted in  figure 1 .
 The standard for quantitating  WZhet was a pCMVneo/WZhet 
plasmid that was linearized using KpnI restriction enzyme (New 
England Biolabs, Beverly, Mass., USA) and purified by standard 
ethanol precipitation. Concentration was determined by UV 
spectrophotometry and a stock standard was prepared at a con-
centration of 1 ng/ml. Since each  WZhet plasmid has one copy of 
the  BZLF1 gene, the copy number of  WZhet DNA in the stock 
aliquots could be determined using  BZLF1 Q-PCR as previously 
described  [21] on serial 10-fold dilutions ranging from 10 –2 to
10 –7 ng/  l of stock. Microsoft Excel was used to obtain a linear 
trend line for the average  BZLF1 viral loads for each serial dilution 
plotted against the concentration of  WZhet  plasmid. It was deter-
mined that the optimal standard curve for our assay relied on six 
serial dilutions ranging in concentration from 5  ! 10 –2 to 5  ! 
10 –7 ng, which corresponds to 1,000,000 to 10  WZhet  DNA copies 
per PCR. In any given run, this curve was considered acceptable 
if a difference of 3.3  8 0.3 cycles was demonstrated between each 
of the 10-fold dilutions, and if the correlation coefficient was at 
least 0.99.
 Q-PCR for  WZhet was performed and products were detected 
using an ABI Prism 7900 or 7500 Real-Time PCR instrument and 
Sequence Detection System software. Thermocycling conditions 
were: 50° for 2 min, 95° for 10 min, 95° for 15 s, and 60° for 1 min 
for 40 cycles. Each 25-  l reaction contained: 1 ! TaqMan Uni-
versal Master Mix, forward and reverse primer (15 pmol each), 
and TaqMan probe (10 pmol). DNA template volume was 1   l 
for paraffin-embedded tissues, and 5   l for plasma samples. To 
check for amplicon contamination, every run contained at least 
two ‘no template’ controls in which nuclease-free water was sub-
stituted for template. Quantification results for experimental 
samples were extrapolated from the standard curve. Experimen-
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 Fig. 1. Map of the  WZhet partially deleted 
and rearranged EBV genome.  WZhet is ap-
proximately 57 kb in length and is com-
posed of four previously non-adjacent seg-
ments of EBV DNA. Two larger segments 
come from the terminal regions and two 
smaller segments from the center portion 
of the viral genome. The two smaller seg-
ments rearrange order with inversion of 
 BZLF1 .  BamH1W and  BZLF1 regions, nor-
mally separated by about 55 kb, become 
juxtaposed. This structural change is 
thought to result in constitutive activation 
of the immediate early gene,  BZLF1 , which 
encodes the major viral protein transacti-
vating lytic gene expression.  
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 Transient Transfection and Virion Measurements in a Cell 
Line Model 
 The AGS gastric cancer cell line (ATCC CRL-1739) was EBV-
infected as previously described using a recombinant form of the 
EBV B95.8 strain  [23–25] . This recombinant virus, courtesy of Dr. 
Henri-Jacques Delecluse of Heidelberg, encodes green fluores-
cence protein and a hygromycin B resistance gene to facilitate se-
lection of infected cells  [23] . The infected clone, AGS-B95-HygB, 
was grown in RPMI 1640 (Gibco, Invitrogen) supplemented with 
100   g/ml hygromycin B (HygB) as well as 10% fetal bovine se-
rum and antibiotics. The level of infection was determined using 
a battery of six EBV Q-PCR assays performed as previously de-
scribed on extracted DNA  [21, 26] , and by  EBER in situ hybridiza-
tion performed on formalin-fixed, paraffin-embedded cell pellets 
that were prepared from the cell line. Immunohistochemical 
stains for EBV lytic proteins (BZLF1 and BMRF1) were performed 
using a BioGenex Super Sensitive non-biotin horseradish peroxi-
dase detection system and BMRF1 antibody (1: 200 dilution; Re-
search Diagnostics, Inc.) or BZLF1 antibody (1: 20 dilution; Ar-
gene).
 To evaluate the extent to which  WZhet could induce lytic viral 
replication, the  WZhet plasmid was transfected into AGS-B95-
HygB gastric cancer cells and then several markers of viral repli-
cation were measured. To accomplish this, cells were plated at a 
density of 1.5  ! 10 5 cells/well. Once they reached 60–80% conflu-
ence, transient transfection of  WZhet plasmid was performed. 
The transfection mixture containing Lipofectamine TM Reagent 
(Invitrogen), 1.5   g of  WZhet plasmid DNA (not linearized), and 
100   l of OptiMEM (Gibco) was incubated for 30 min at room 
temperature. During preparation of the transfection mixture, the 
cells were starved in serum-free RPMI 1640 medium for 30 min 
at 37° in a humidified atmosphere with 5% CO 2 . The starvation 
medium was replaced with serum-free medium and the 
Lipofectamin TM / WZhet transfection mixture. The plates were in-
cubated for 2 h at 37° in a humidified atmosphere with 5% CO 2 . 
To show that hygromycin B did not affect the transfection rate or 
the level of viral replication in the AGS-B95-HygB cells, the trans-
fection was performed again in the presence of 100   g/ml hygro-
mycin B. Following transfection, the cells were propagated in 
growth media for 2 days and DNA was harvested from superna-
tants and cells.
 Before harvesting DNA from supernatant fractions, virions 
were separated from naked viral DNA based on differential deg-
radation by DNase, as previously described  [22] . In short, DNA 
unprotected by a capsid was targeted for degradation by treating 
the supernatant (200   l) with 25   l DNase (DNase RQ1, Promega, 
Madison, Wisc., USA) for 1 h followed by an additional 25   l DN-
ase for a second hour at 37°. Stop Buffer (Promega) and incubation 
at 56° served to inactivate the enzyme. DNA was isolated from cell 
pellets and from supernatants (DNase-treated and untreated) us-
ing the QiaAmp Mini DNA Kit (Qiagen).  WZhet Q-PCR was used 
to verify that  WZhet plasmid DNA was transfected into the cells. 
 BamH1W Q-PCR assay was used to measure EBV DNA, and the 
percentage of EBV DNA remaining post-DNase treatment (e.g. 
virion DNA) was calculated. The human  APOB Q-PCR assay was 
used as a control to ensure that the DNase enzyme was working 
efficiently.
 Results 
 Assay Linearity, Sensitivity, and Reproducibility 
 A quantitative real-time PCR assay targeting EBV 
 WZhet DNA was developed for sensitive and precise 
measurement of  WZhet DNA. Using linearized plasmid 
as the standard, the assay was efficient as shown by a cy-
cle difference of 3.3 or 3.4 for each serial 10-fold dilution 
(representing slope of the standard curve). In addition, 
the assay was linear across 5 orders of magnitude as 
shown by a correlation coefficient  1 0.99 (representing 
the linearity of the standard curve). The WZhet Q-PCR 
assay was sensitive, detecting as few as 10 copies per PCR 
of this defective form of the EBV genome. Reproducibil-
ity of the assay was examined by replicate testing of the 
linearized  WZhet DNA standards at each of the six serial 
dilution standards in duplicate on 10 different days, and 
the average cycle threshold value was used to calculate a 
coefficient of variance of 2%, suggesting that the assay is 
quite precise and reproducible. 
 Undetectable EBV  WZhet DNA in vivo 
 A series of 287 paraffin-embedded tissue samples (39 
 EBER -positive lesions and 248  EBER -negative tissues) 
were tested for EBV  WZhet DNA by Q-PCR. These in-
cluded a wide variety of lesions whose histopathologic 
classification and  EBER status are listed in  tables 1 and  2 . 
For simplicity, only a sampling of  EBER -negative tumors 
and various benign tissues are shown in  table 2 . Surpris-
ingly,  WZhet  DNA was not detected by the  WZhet Q-
PCR assay in any of the tissues examined in this study. A 
control Q-PCR targeting the human  APOB gene verified 
that DNA had been extracted from each sample and was 
available for amplification. The  APOB assay also serves 
as a gauge of the number of cells assayed from each tissue 
block, and in this series there was a range from 94 to 
69,917 cells (mean 12,800) per tissue that was represented 
in the amplification reactions. These findings suggest 
that  WZhet  is not commonly found in the spectrum of 
lesions that was examined in vivo regardless of whether 
the lesion contains latent EBV (e.g. various  EBER -positive 
lymphomas and carcinomas) or lytic EBV (e.g. oral hairy 
leukoplakia).
 To evaluate whether  WZhet  DNA was circulating in 
the bloodstream as cell-free DNA, a series of 37 plasma 
samples were assayed for  WZhet by Q-PCR. None of the 
37 plasmas had detectable  WZhet  DNA to a sensitivity of 
10 copies per PCR. These plasma samples were from pa-
tients with various EBV-related disorders (n = 28) and 
from healthy blood donors (n = 9). These samples were 
 Ryan /Jones /Elmore /Kenney /Miller /
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1 Oral hairy leukoplakia 1,243 2,624,346 0
2 Oral hairy leukoplakia 18,382 1,142 0
3 Oral hairy leukoplakia 5,782 2,292 0
4 Oral hairy leukoplakia 2,433 15,231 0
5 Oral hairy leukoplakia 3,635 1,018 0
6 Oral hairy leukoplakia 3,128 3,608,042 0
7 Oral hairy leukoplakia 1,180 297 0
8 Oral hairy leukoplakia 14,732 6,889,764 0
9 AIDS lymphoma 915 125 0
10 AIDS lymphoma 11,409 48,540 0
11 AIDS lymphoma 2,228 631,239 0
12 AIDS lymphoma 209 2,392 0
13 AIDS lymphoma 592 349,493 0
14 Hodgkin, AIDS-related 3,633 2,697 0
15 Hodgkin, AIDS-related 979 3,575 0
16 Hodgkin, AIDS-related 4,032 397 0
17 Hodgkin lymphoma 7,666 75 0
18 Hodgkin lymphoma 467 14 0
19 Hodgkin lymphoma 1,803 86 0
20 Hodgkin lymphoma 18,058 2,226 0
21 Hodgkin lymphoma 94 0 0
22 Non-Hodgkin lymphoma 1,501 41,173 0
23 Non-Hodgkin lymphoma 6,178 58,514 0
24 Nasopharyngeal carcinoma 6,935 250,397 0
25 Nasopharyngeal carcinoma 69,917 23,047 0
26 Post-transplant LPD 6,559 15,612 0
27 Post-transplant LPD 2,733 5,269 0
28 Post-transplant LPD 2,778 25,054 0
29 Gastric adenocarcinoma 2,974 44,956 0
30 Gastric adenocarcinoma 271 200,000 0
31 Gastric adenocarcinoma 2,896 90,919 0
32 Gastric adenocarcinoma 1,198 193,823 0
33 Gastric adenocarcinoma 2,734 144,221 0
34 Gastric adenocarcinoma 80,033 117,755 0
35 Gastric adenocarcinoma 8,770 130,935 0
36 Gastric adenocarcinoma 23,209 70,757 0
37 Gastric adenocarcinoma 38,723 112,875 0
38 Gastric adenocarcinoma 5,623 44,496 0
39 Gastric adenocarcinoma 2,812 64,047 0
Table 2. WZhet and total EBV  (BamH1W) levels in selected paraf-









40 AIDS lymphoma 32,544 34 0
41 AIDS lymphoma 12,626 8 0
42 AIDS lymphoma 50,966 57 0
43 AIDS lymphoma 41,928 0 0
44 AIDS lymphoma 14,180 21 0
45 AIDS lymphoma 18,094 6 0
46 AIDS lymphoma 60,348 5 0
47 Hodgkin, AIDS-related 11,660 17 0
48 Hodgkin lymphoma 1,551 0 0
49 Hodgkin lymphoma 643 0 0
50 Hodgkin lymphoma 4,203 0 0
51 Hodgkin lymphoma 1,182 0 0
52 Gastric adenocarcinoma 4,109 0 0
53 Gastric adenocarcinoma 3,289 9 0
54 Gastric adenocarcinoma 1,875 0 0
55 Gastric adenocarcinoma 11,655 17 0
56 Gastric adenocarcinoma 2,148 93 0
57 Gastric adenocarcinoma 45,494 4 0
58 Gastric adenocarcinoma 10,035 0 0
59 Gastric adenocarcinoma 13,933 1 0
60 Gastric adenocarcinoma 1,744 0 0
61 Gastric adenocarcinoma 225 222 0
62 Gastric adenocarcinoma 19,857 29 0
63 Gastric adenocarcinoma 23,224 142 0
64 Adult gastritis 5,726 271 0
65 Adult gastritis 7,612 66 0
66 Adult gastritis 1,445 0 0
67 Adult gastritis 6,529 3 0
68 Adult gastritis 1,299 108 0
69 Pediatric gastritis 401 0 0
70 Pediatric gastritis 558 18 0
71 Pediatric gastritis 136 37 0
72 Pediatric gastritis 317 0 0
73 Crohn’s disease 1,238 0 0
74 Crohn’s disease 9,278 10 0
75 Crohn’s disease 277 0 0
76 Crohn’s disease 5,568 0 0
77 Ulcerative colitis 7,035 71 0
78 Ulcerative colitis 748 2,406 0
79 Ulcerative colitis 33,311 0 0
80 Ulcerative colitis 6,488 77 0
81 Meningioma 27,956 0.4 0
82 Meningioma 54,614 0 0
83 Normal gastric mucosa 5,150 0 0
84 Normal gastric mucosa 11,326 0 0
85 Normal colon mucosa 7,686 3 0
86 Normal colon mucosa 9,853 0 0
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assayed for  WZhet DNA and were also tested for tradi-
tional EBV viral load by  BamH1W Q-PCR. The EBV-re-
lated disorders included AIDS lymphoma (n = 10), EBV-
positive post-transplant lymphoproliferative disorder
(n = 6), and infectious mononucleosis (n = 12) cases
having plasma  BamH1W viral loads ranging from 0 to 
81,000 copies/ml for the AIDS lymphoma cases, from 308 
to 119,000 copies/ml for post-transplant lymphoprolifer-
ative disorders, and from 49 to 13,000 copies/ml for infec-
tious mononucleosis cases. In contrast, the healthy blood 
donors (n = 9) had no detectable plasma  BamH1W  DNA 
to a sensitivity of 5 copies of EBV DNA per PCR, which 
translates to no  BamH1W  DNA to a sensitivity of 250 
copies/ml of plasma. To show that DNA was extracted 
from plasma and that no significant inhibitors were pres-
ent, each plasma sample had been spiked with an exo-
genous non-human DNA prior to extraction, and this 
spiked DNA was consistently amplified among the 37 
plasma samples. The absence of  WZhet in all 37 plasma 
samples as well as all 287 biopsy tissues implies that 
 WZhet is not commonly present in the spectrum of le-
sions evaluated in vivo even when EBV infection is abun-
dantly present as shown by traditional  EBER or EBV viral 
load assays.
 Detection of  WZhet DNA in vitro 
 The failure to detect  WZhet DNA in any of the biopsy 
or plasma samples examined suggests that this defective 
form of EBV is rare in vivo. An alternative explanation 
for our failure to detect  WZhet  could be technical failure 
of our assay. In particular, the plasmid insert used for de-
sign and control of our assay may not represent the typi-
cal  WZhet structure that is present in vivo even though it 
was cloned from the prototypic P3HR1 cell line which, in 
turn, was derived from a human lymphoma. It should be 
noted, however, that this plasmid amplified with all three 
of our Q-PCR assays (targeting  BZLF1 ,  BamH1W , and 
 WZhet) , confirming these sequences were present.
 To show that the  WZhet plasmid could induce EBV 
replication in vitro, the plasmid was transfected into an 
EBV-infected gastric cancer cell line, AGS-B95-HygB, 
which was then examined for the effect on expression of 
replicative viral genes  ( BZLF1 and  BMRF1 ) and on the 
level of intact virions in the supernatant. Before transfec-
tion was performed, baseline tests were performed on the 
AGS-B95-HygB using six EBV Q-PCR assays that target 
six disparate segments of the viral genome. The AGS-
B95-HygB line had high viral load by all six Q-PCR as-
says.  WZhet DNA was also detected by Q-PCR, suggest-
ing that  WZhet is produced in infected cells that are cul-
tured in vitro where the human immune response is 
absent ( table 3 ). Furthermore,  EBER  in situ hybridization 
showed  EBER expression in 90% of the AGS-B95-HygB 
confirming that these cells were indeed infected. BZLF1 
and BMRF1 histochemical stains showed that approxi-
mately 35% of cells expressed these replicative viral pro-
teins at baseline.
 Despite the baseline presence of  WZhet  DNA, a tran-
sient transfection was performed to determine if viral 
replication could be further induced by the  WZhet plas-
mid. As shown in  table 3 , successful transfection of the 
 WZhet  plasmid occurred as shown by increased levels of 
WZhet  by Q-PCR of DNA extracted from cell pellets . To-
tal EBV genomes, as measured by  BamH1W levels, like-
wise rose upon transfection, particularly in the superna-
tant where EBV levels rose more than 2-fold.
 To determine if the viral DNA in the supernatant rep-
resented encapsidated virions, virion production was de-
termined by measuring  BamH1W load by Q-PCR in the 










Before WZhet plasmid transfection
Cells 90,359 385,904 1,476
Supernatant 987 86,460 2
After WZhet plasmid transfection
Cells 67,602 460,256 4,182,500
Supernatant 791 207,984 1,020,427
All values represent the number of genomes (i.e., cellular, EBV, or rearranged EBV) 
per PCR.
Table 3. EBV DNA and human DNA 
control levels in the AGS-B95-HygB 
gastric cancer cell line before and after 
WZhet plasmid transfection
 Ryan /Jones /Elmore /Kenney /Miller /
Schroeder /Gulley 
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zyme. Our prior validation work showed that the capsid 
protects virions from digestion by DNase I enzyme, so 
any detectable EBV DNA remaining in the supernatant 
post-digestion represents virion DNA. A substantial pro-
portion of the viral DNA (57%) was DNase I-resistant, 
suggesting that virion production was induced by AGS-
B95-HygB cells upon  WZhet transfection ( fig. 2 ). Inter-
estingly, both naked EBV DNA and encapsidated EBV 
DNA rose in equal proportions after transfection, where-
as human  APOB levels did not rise, implying that the na-
ked DNA is not derived from dying cells rather it appears 
to represent EBV DNA that failed to acquire a capsid. 
These findings demonstrate that the  WZhet  plasmid can 
induce viral replication when coexpressed with the wild-
type EBV genome.
 Discussion 
 In this study, there was no evidence that human tissues 
contain the  WZhet form of the EBV genome when tested 
for by a novel Q-PCR assay. No  WZhet  DNA was detect-
ed in any of the benign (n = 134) or malignant (n = 153) 
paraffin-embedded tissues screened in our study, nor 
was it found in plasma samples from patients with EBV-
related disorders (n = 28) or healthy controls (n = 9). This 
result implies that the rearranged, partially deleted 
 WZhet DNA is rarely present in human tissues. This 
finding is important because it refutes the postulate that 
this atypical form of EBV DNA is commonly present
in human tissues that were negative for EBV by more tra-
ditional laboratory tests. Furthermore, it implies that 
 WZhet does not commonly coexist with the more tradi-
tional  EBER -expressing viral genome in several types of 
lesions that have not been previously examined for pres-
ence of  WZhet . Furthermore, it implies that  WZhet is not 
commonly present in several types of EBV-related tu-
mors that have not been previously examined for coexis-
tence of  WZhet .
 Other novel aspects of this study were (1) the develop-
ment and application of a real-time PCR assay to detect 
and quantify  WZhet , and (2) the first demonstration that 
epithelial cells are susceptible to induction of lytic viral 
replication upon transfection by  WZhet , whereas prior 
studies had shown this effect only in lymphoid cells. The 
rather modest extent of viral induction in AGS epithelial 
cells was similar to the modest degree of rise in EBV DNA 
reported when B95.8 lymphoid cell lines, which also har-
bor baseline viral replication, are induced to replicate 
further by 12- O -tetradecanoylphorbol-13-acetate (TPA) 
 [27] .
 Our clinical findings are somewhat at odds with sev-
eral previous studies that reported finding  WZhet DNA 
in Burkitt lymphoma, oropharyngeal lesions,  EBER -neg-
ative and  EBER -positive Hodgkin lymphoma, thymic 
carcinoma, and idiopathic pulmonary fibrosis  [6, 13, 15, 
16, 19, 20] . In support of previous findings, Kelly et al.  [13, 
28] detected  WZhet DNA in the peripheral blood and 
lung tissue of patients suffering from idiopathic pulmo-
nary fibrosis, although the role of EBV in idiopathic pul-
monary fibrosis remains uncertain  [29] . Kelly et al.  [13] 
also demonstrated that  WZhet DNA was always associ-
ated with the presence of other EBV DNA, suggesting 
that the defective viral genome cannot exist without the 
standard EBV genome. It should be noted that the current 
study did not include pulmonary fibrosis and several oth-
er disease entities with which WZhet was previously as-
sociated.
 In agreement with our study, Knecht and Odermatt 
 [30] also found no detectable  WZhet DNA in EBV-posi-
tive Hodgkin lymphoma, and the discrepancy with prior 
work was explained, at least in part, by a difference in
the age of patients, since Gan et al.  [6] had shown  WZhet 
DNA on patients who were less than 21 years old at diag-
nosis whereas Knecht and Odermatt  [30]  studied adults. 
Loss of defective genomes was hypothesized to correlate 
with differences in immunity between children and 

























 Fig. 2. EBV  WZhet plasmid induces viral replication in AGS-B95-
HygB gastric cancer cells. A large percentage of EBV DNA was not 
digested by DNase I in AGS-B95-HygB cell supernatant, suggest-
ing active viral replication with virion production.  WZhet plas-
mid transfection more than doubled the number of virions pro-
duced by AGS-B95-HygB cells. 
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 Technical factors could also explain the observed dis-
crepancies. Prior studies generally used PCR followed by 
Southern blot analysis, and ours is the first study to use 
quantitative PCR  [14, 15, 17, 20] . One cannot exclude the 
possibility that naturally occurring WZhet has alternative 
recombination junctions or polymorphisms that render it 
non-amplifiable by our assay, particularly since our assay 
amplifies a segment of only 149 bp flanking the recombi-
nation site within the P3HR1 standard. In support of the 
validity of our new assay is the detection of  WZhet in in-
fected AGS cells as well as detection of prototypic WZhet 
derived from P3HR1 cells. Assay specificity was assured 
by application of an internal TaqMan probe that simulta-
neously permits quantification of accumulating ampli-
cons against a standard prepared from a plasmid insert of 
the prototypic P3HR1 Burkitt lymphoma cell line. Our as-
say was sensitive to as few as 10 copies of  WZhet  per PCR, 
which is probably similar to the sensitivity levels achieved 
in prior studies in which PCR followed by Southern blot 
analysis was used, although prior work was done on fresh 
or frozen tissue as opposed to the paraffin-embedded tis-
sue that we targeted. To assure that amplifiable DNA was 
recovered, we applied a second PCR of the human  APOB 
gene that verified the efficacy of DNA extraction and am-
plification from each paraffin-embedded tissue.
 WZhet has been shown to be unstable in uninfected 
cell lines as well as in the P3HR1 Burkitt cell line. So, even 
if  WZhet were formed in vivo, it could be lost, particu-
larly if it activates viral replication and thereby elicits a 
host immune response  [31–35] . In this regard, one might 
expect to see it more commonly in immunocompromised 
individuals where uncontested survival of infected cells 
appears to be more frequent. However,  WZhet was not 
detectable in AIDS or allogenic transplant patients, even 
those who harbored EBV-related malignancies and who 
were clearly unable to control the proliferation of latently 
infected cells. Furthermore,  WZhet was not detected in 
our post-transplant lymphoproliferations or in two ul-
cerative colitis tissues focally expressing the lytic viral 
proteins BZLF1 and BMRF1 (data not shown), suggesting 
that  WZhet  is not the explanation for activated infection 
in these lesions. Finally,  WZhet  was not detected in pri-
mary EBV infection even though infectious mononucle-
osis patients are only just developing the antibody and 
cell-mediated immune reactions that will protect them 
from rampant latent and lytic EBV infection for the dura-
tion of their lives. In contrast to the in vivo samples, 
 WZhet DNA was detected in cultured AGS-B95-HygB 
gastric cancer cells. This supports the hypothesis that 
 WZhet DNA occurs in the absence of selective pressures 
enforced by a host immune system.
 In summary, our findings support a role for EBV 
WZhet DNA in inducing viral replication in vitro. How-
ever, our inability to detect EBV  WZhet DNA in any of 324 
plasma or tissue samples, including those with latent or 
lytic EBV infection, suggests that either  WZhet  is not 
formed in the spectrum of lesions examined in vivo or 
that it exists only transiently. The findings serve to em-
phasize that in vitro EBV infection in cell culture does not 
necessarily mimic in vivo EBV infection in a living host.
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